Skip to search formSkip to main contentSkip to account menu

Somatropin 5 MG/ML Injectable Solution [Omnitrope]

Known as: SOMATROPIN 5 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Omnitrope], Omnitrope KIT, Omnitrope 5 MG/ML Injectable Solution 
National Institutes of Health

Related topics

Related topics

18 relations
Benzyl AlcoholBrain NeoplasmsCachexiaCongestive heart failure

Broader (1)

Pituitary Hormones, Anterior

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort
Purpose To investigate the long-term safety (primary endpoint) and effectiveness (secondary endpoint) of the somatropin… 
2019
2019
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational…
BackgroundTo evaluate the impact of treatment with recombinant human growth hormone (rhGH; Omnitrope®) on the risk of diabetes… 
Review
2017
Review
2017
Patients’ perceptions on the usability of the SurePal™ self-injection device for Omnitrope®: a questionnaire-based observational study conducted in paediatric patients in France
Background: A questionnaire-based survey was conducted to evaluate attitudes towards a reusable self-injection system, SurePal… 
2017
2017
Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study
PurposeTo report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope®, a somatropin… 
2016
2016
Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study
BackgroundPATRO Children is an ongoing observational, longitudinal, non-interventional, global post-marketing surveillance study… 
Review
2015
Review
2015
Acceptability of the reusable SurePal™ self-injection device for Omnitrope® among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study
Background SurePal™ is a reusable self-injection system that has been developed to support daily administration of Omnitrope… 
2013
2013
Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study
Close adherence to the recommended treatment regimen is important for the success of recombinant human growth hormone therapy… 
2013
2013
Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis
Background Treatment of growth hormone disorders typically involves daily injections of human growth hormone (GH) over many years… 
Review
2011
Review
2011
Experience of reviewing the follow-on biologics including Somatropin and erythropoietin in Japan.
2010
2010
human growth hormone Omnitrope ® and the original lyophilized formulations for reconstitution of Omnitrope ® and Genotropin ®
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)